<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04353986</url>
  </required_header>
  <id_info>
    <org_study_id>CL30114</org_study_id>
    <nct_id>NCT04353986</nct_id>
  </id_info>
  <brief_title>PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders</brief_title>
  <official_title>Pharmacokinetics of Sofosbuvir and Ledipasvir in Hepatitis C Virus - Infected Adolescent Patients With Haematological Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, controlled, open-label, pharmacokinetic study. This study aims at
      studying the PK of sofosbuvir, ledipasvir and sofosbuvir metabolite (GS-331007) in HCV
      infected children with hematological Disorders. to develop predictive pharmacokinetic model
      for the 3 moieties in the studied population.

      In this study, patients in both treatment groups will receive 12 weeks of treatment with a
      fixed-dose combination tablet containing 400 mg of sofosbuvir and 90 mg of
      ledipasvir(SOF/LED) orally, once daily with food.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, patients in both treatment groups will receive 12 weeks of treatment with a
      fixed-dose combination tablet containing 400 mg of sofosbuvir and 90 mg of
      ledipasvir(SOF/LED) orally, once daily with food, as prescribed by the attending physician.
      Twelve eligible HCV-infected patients with hematological disorder and 12 matching HCV control
      patients without haematological disorder or comorbidities will be enrolled in the study. At
      baseline, careful history of the recruited patients including demographic characteristics
      (age, height, weight, and gender), comorbidities, medication history, familial history,
      social history, blood transfusion history, and baseline laboratory tests will be documented.

      The baseline laboratory tests will include renal function tests (serum creatinine), liver
      function tests (bilirubin, albumin, AST, and ALT), international normalised ratio (INR),
      alpha fetoprotein (AFP), complete blood count (CBC), degree of liver fibrosis by
      Fibroscan,viral load by PCR and HCV genotype Follow-up will be done for all participants at
      baseline, after 10 days of treatment for the evaluation of the steady state PK parameters of
      SOF/LED in those patients, after 12 weeks of treatment, and after 12 weeks from the end of
      treatment. For a total of 4 follow-up visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective, interventional, controlled, open-label, pharmacokinetic study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Predictive Pharmacokinetic Model</measure>
    <time_frame>10 days</time_frame>
    <description>serial blood samples will be withdrawn to measure the drug level develop a Predictive Pharmacokinetic Model for sofosbuvir, ledipasvir and GS 331007</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sustained virologic response</measure>
    <time_frame>6 months</time_frame>
    <description>sustained virologic response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse drug reactions</measure>
    <time_frame>3 months</time_frame>
    <description>record any adverse drug reactions experienced by the patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>HCV Infection</condition>
  <condition>Beta Thalassemia Major</condition>
  <arm_group>
    <arm_group_label>Beta thalassemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV infected Beta thalassemia major adolescents</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HCV infected, otherwise healthy, sex and age matched to the thalassemia group serving as control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir and Ledipasvir</intervention_name>
    <description>fixed dose tablet containing 400 mg sofosbuvir and 90 mg ledipasvir</description>
    <arm_group_label>Beta thalassemia</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>SOF/LED</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria:

          -  Adolescents (ages 12-18 years) and/ or weight more than 35 Kg

          -  Diagnosed with beta-thalassemia major and receiving regular blood transfusion

          -  spleenectomised

          -  Chronic HCV infection (defined as more than 6 months history of the disease)

          -  Na√Øve non-cirrhotic population with FIB Score: F0 to F3 as measured by Fibroscan

          -  Screening laboratory values of the beta-thalassemia group within the following
             thresholds (absolute neutrophil count &gt; 1500/mm3, platelets &gt; 7500 cells/mm3 , Serum
             creatinine &lt; 1.2 mg/dl, creatinine clearance &gt; 40 mL/min, albumin &gt;3.5 gm/dl, and
             aspartate transaminase (AST) and alanine transaminase (ALT) level less than 5 fold of
             the normal limit). Control group should have normal biochemical profile.

          -  Assent of the patients and consent of their legal guardians are required

        Exclusion Criteria:

          -  Previous treatment for HCV.

          -  History of clinically significant illness or any other medical disorder that may
             interfere with individual's treatment, assessment or compliance with the protocol or
             affect the pharmacokinetics of the study drugs. Such as,

               -  Ongoing or untreated cancer including haematologic and hepatic cancers

               -  Co-infection with human immunodeficiency virus (HIV), acute hepatitis A virus or
                  hepatitis B virus

               -  Clincal hepatic decompensation (i.e., ascites, encephalopathy or variceal
                  haemorrhage)

               -  Renal dysfunction

               -  Active infection (any infection showing clinical manifestation at time of
                  sampling)

          -  Known hypersensitivity to study medications

          -  Ongoing treatment with cyclosporine, rifampin, phenytoin, carbamazepine,
             phenobarbital, or amiodarone.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manal H El-Sayed, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of MARSI-CRC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manal H El-Sayed, M.D.</last_name>
    <phone>01227461120</phone>
    <phone_ext>002</phone_ext>
    <email>manalhelsayed@yahoo.co.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fatma S Ebeid, M.D.</last_name>
    <phone>01095569596</phone>
    <phone_ext>002</phone_ext>
    <email>dr.fatma_ebeid@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Masri-Crc</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manal H El-Sayed, M.D.</last_name>
      <phone>01227461120</phone>
      <phone_ext>002</phone_ext>
      <email>manalhelsayed@yahoo.co.uk</email>
    </contact>
    <contact_backup>
      <last_name>Fatma S Ebeid, M.D.</last_name>
      <phone>01095569596</phone>
      <phone_ext>002</phone_ext>
      <email>dr.fatma_ebeid@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eman A El-Baraky, Ms.C.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nirmeen A Sabry, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maggie M Abbassi, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Manal Hamdy El-Sayed</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hepatitis C virus</keyword>
  <keyword>Pharmacokinetic Modeling</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Sofosbuvir</keyword>
  <keyword>Ledipasvir</keyword>
  <keyword>Direct acting antivirals</keyword>
  <keyword>Beta thalassemia major</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
    <mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

